Valuation: Coya Therapeutics, Inc.

Market Cap 73.42M 66.54M 61.54M 55.53M 105M 6.92B 108M 739M 293M 3.7B 276M 270M 11.74B P/E 2026 *
-2.08x
P/E 2027 * -2.06x
Enterprise Value 73.42M 66.54M 61.54M 55.53M 105M 6.92B 108M 739M 293M 3.7B 276M 270M 11.74B EV / Sales 2026 *
92.2x
EV / Sales 2027 * 14.6x
Free-Float
83.27%
Yield 2026 *
-
Yield 2027 * -
1 day-4.28%
1 week+4.68%
Current month-13.30%
1 month-30.06%
3 months-32.98%
6 months-31.06%
Current year-46.03%
1 week 2.92
Extreme 2.925
3.47
1 month 2.72
Extreme 2.72
4.54
Current year 2.72
Extreme 2.72
6.21
1 year 2.72
Extreme 2.72
6.62
3 years 2.72
Extreme 2.72
10.69
5 years 2.72
Extreme 2.72
10.69
10 years 2.72
Extreme 2.72
10.69
Manager TitleAgeSince
Chief Executive Officer 57 31/10/2024
President 67 16/07/2023
Director of Finance/CFO 65 29/03/2022
Director TitleAgeSince
Director/Board Member 58 28/02/2021
Director/Board Member 67 24/05/2021
Director/Board Member 64 31/05/2021
Date Insider Type Main position Quantity % Market Cap. Importance
09/04/26 Free

Director

10,000 0.0426%
22/01/26 Free

Chief Financial Officer

140,041 0.6693%
22/01/26 Free

Chief Executive Officer

15,257 0.0729%
Change 5-day change 1-year change 3-year change Capi.($)
-4.28%+4.68%-47.48%-37.52% 73.42M
-2.69%-0.48%+51.67%+69.09% 66.33B
-0.92%+7.67%+14.26%+90.92% 60.62B
0.00%+0.39%+20.52%+98.45% 55.5B
+0.14%+2.35%+13.08%+109.47% 47.58B
-2.21%-2.47%+18.60%+36.89% 43.69B
-2.30%-10.40%+167.61%+776.79% 37.27B
+2.15%+1.42%+15.17%+56.49% 36.57B
-2.32%-2.24%+75.52%+52.70% 32.22B
+2.62%+5.90%-36.55%+406.95% 26.58B
Average -0.98%+0.51%+29.24%+166.02% 41B
Weighted average by Cap. -0.83%+0.20%+37.21%+162.15%

Financials

2026 *2027 *
Net sales 797K 722K 668K 603K 1.14M 75.12M 1.18M 8.02M 3.18M 40.13M 2.99M 2.93M 127M 5.04M 4.57M 4.22M 3.81M 7.18M 475M 7.44M 50.75M 20.12M 254M 18.91M 18.51M 806M
Net income -35.11M -31.81M -29.42M -26.55M -50.03M -3.31B -51.79M -353M -140M -1.77B -132M -129M -5.61B -35.76M -32.4M -29.97M -27.04M -50.96M -3.37B -52.75M -360M -143M -1.8B -134M -131M -5.72B
Net Debt - -
Projected Income Statement - Annual - Coya Therapeutics, Inc.
Logo Coya Therapeutics, Inc.
Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in developing treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The Company's 300 Series product candidates include COYA 301 and COYA 302.
Employees
8
Date Price Change Volume
13/11/26 US$3.130 -4.28% 189,168
12/11/26 US$3.270 +1.87% 141,124
11/11/26 US$3.210 +1.58% 89,966
10/11/26 US$3.160 -5.11% 200,525
09/11/26 US$3.330 +11.37% 222,820
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Coya Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.130USD
Average target price
15.21USD
Spread / Average Target
+386.08%
  1. Stock Market
  2. Stocks
  3. COYA Stock